282 related articles for article (PubMed ID: 19944974)
1. Glioma stem cell research for the development of immunotherapy.
Ji J; Black KL; Yu JS
Neurosurg Clin N Am; 2010 Jan; 21(1):159-66. PubMed ID: 19944974
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.
Ji J; Judkowski VA; Liu G; Wang H; Bunying A; Li Z; Xu M; Bender J; Pinilla C; Yu JS
Stem Cells Transl Med; 2014 Mar; 3(3):356-64. PubMed ID: 24375541
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
4. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
5. The role of cancer stem cells (CD133(+)) in malignant gliomas.
Cho DY; Lin SZ; Yang WK; Hsu DM; Lin HL; Lee HC; Lee WY; Chiu SC
Cell Transplant; 2011; 20(1):121-5. PubMed ID: 20887676
[TBL] [Abstract][Full Text] [Related]
6. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma.
Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I
Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699
[TBL] [Abstract][Full Text] [Related]
7. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
Liu Q; Nguyen DH; Dong Q; Shitaku P; Chung K; Liu OY; Tso JL; Liu JY; Konkankit V; Cloughesy TF; Mischel PS; Lane TF; Liau LM; Nelson SF; Tso CL
J Neurooncol; 2009 Aug; 94(1):1-19. PubMed ID: 19468690
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies.
Denysenko T; Gennero L; Roos MA; Melcarne A; Juenemann C; Faccani G; Morra I; Cavallo G; Reguzzi S; Pescarmona G; Ponzetto A
Cell Biochem Funct; 2010 Jul; 28(5):343-51. PubMed ID: 20535838
[TBL] [Abstract][Full Text] [Related]
9. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.
Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K
J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844
[TBL] [Abstract][Full Text] [Related]
10. Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell-Engaging Antibody and CD8 T Cells.
Prasad S; Gaedicke S; Machein M; Mittler G; Braun F; Hettich M; Firat E; Klingner K; Schüler J; Wider D; Wäsch RM; Herold-Mende C; Elsässer-Beile U; Niedermann G
Cancer Res; 2015 Jun; 75(11):2166-76. PubMed ID: 25840983
[TBL] [Abstract][Full Text] [Related]
11. The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma.
Vora P; Venugopal C; Salim SK; Tatari N; Bakhshinyan D; Singh M; Seyfrid M; Upreti D; Rentas S; Wong N; Williams R; Qazi MA; Chokshi C; Ding A; Subapanditha M; Savage N; Mahendram S; Ford E; Adile AA; McKenna D; McFarlane N; Huynh V; Wylie RG; Pan J; Bramson J; Hope K; Moffat J; Singh S
Cell Stem Cell; 2020 Jun; 26(6):832-844.e6. PubMed ID: 32464096
[TBL] [Abstract][Full Text] [Related]
12. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas.
Joo KM; Kim SY; Jin X; Song SY; Kong DS; Lee JI; Jeon JW; Kim MH; Kang BG; Jung Y; Jin J; Hong SC; Park WY; Lee DS; Kim H; Nam DH
Lab Invest; 2008 Aug; 88(8):808-15. PubMed ID: 18560366
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy targeting glioma stem cells--insights and perspectives.
Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous phenotype of human glioblastoma: in vitro study.
Denysenko T; Gennero L; Juenemann C; Morra I; Masperi P; Ceroni V; Pragliola A; Ponzetto A; Melcarne A
Cell Biochem Funct; 2014 Mar; 32(2):164-76. PubMed ID: 23836332
[TBL] [Abstract][Full Text] [Related]
16. [Preliminary interpretation on the relationship between the phenotype of CD133+ cells and niche in transplanted human glioma in mice].
Song WC; Fei XF; Dong J
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):564-9. PubMed ID: 21122405
[TBL] [Abstract][Full Text] [Related]
17. Brain tumor stem cells from an adenoid glioblastoma multiforme.
Oka N; Soeda A; Noda S; Iwama T
Neurol Med Chir (Tokyo); 2009 Apr; 49(4):146-50; discussion 150-1. PubMed ID: 19398857
[TBL] [Abstract][Full Text] [Related]
18. Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody.
Wang CH; Chiou SH; Chou CP; Chen YC; Huang YJ; Peng CA
Nanomedicine; 2011 Feb; 7(1):69-79. PubMed ID: 20620237
[TBL] [Abstract][Full Text] [Related]
19. [The CD133 polyclonal antibody generation and cancer stem cells identification].
Tian JL; Cai PL; Xia XQ; Li FH; Wang DH; Chen MN
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 May; 42(3):422-6. PubMed ID: 21827013
[TBL] [Abstract][Full Text] [Related]
20. Development of a novel imaging agent using peptide-coated gold nanoparticles toward brain glioma stem cell marker CD133.
Cho JH; Kim AR; Kim SH; Lee SJ; Chung H; Yoon MY
Acta Biomater; 2017 Jan; 47():182-192. PubMed ID: 27721007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
